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Abstract: Infections after orthopedic surgery are a very unwelcome outcome; despite the 
widespread use of antibiotics, their incidence can be as high as 10%. This risk is likely to 
increase as antibiotics are gradually losing efficacy as a result of bacterial resistance; therefore, 
novel antimicrobial approaches are required. Parabens are a class of compounds whose anti-
microbial activity is employed in many cosmetic and pharmaceutical products. We developed 
propylparaben nanoparticles that are hydrophilic, thus expanding the applicability of parabens 
to aqueous systems. In this paper we assess the possibility of employing paraben nanoparticles 
as antimicrobial compound in bone cements. The nanoparticles were embedded in various types 
of bone cement (poly(methyl methacrylate) [PMMA], hydroxyapatite, and brushite) and the anti-
microbial activity was determined against common causes of postorthopedic surgery infections 
such as: Staphylococcus aureus, methicillin-resistant S. aureus, Staphylococcus epidermidis, and 
Acinetobacter baumannii. Nanoparticles at concentrations as low as 1% w/w in brushite bone 
cement were capable of preventing pathogens growth, 5% w/w was needed for hydroxyapatite 
bone cement, while 7% w/w was required for PMMA bone cement. No  detrimental effect was 
determined by the addition of paraben nanoparticles on bone cement compression strength and 
cytocompatibility. Our results demonstrate that paraben nanoparticles can be encapsulated in 
bone cement, providing concentration-dependent antimicrobial activity; furthermore, lower 
concentrations are needed in calcium phosphate (brushite and hydroxyapatite) than in acrylic 
(PMMA) bone cements. These nanoparticles are effective against a wide spectrum of bacteria, 
including those already resistant to the antibiotics routinely employed in orthopedic applica-
tions, such as gentamicin.
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Introduction
Some microorganisms, a small fraction, can induce adverse effects on humans and 
are known as pathogens. The outcomes of an infection can range from pain and fever 
to death, depending on the microorganism and the physiological characteristics of 
the patient affected. Until the discovery of antibiotics by Alexander Fleming in the 
late 1920s, infections were almost untreatable and one of the most common causes 
of death; for instance, even a small superficial cut could have resulted in a fatality. 
Moreover, until that time surgical procedures had limited efficacy, as infections quickly 
developed in the majority of cases.
Antibiotics were hailed as the solution of infections; however, such beliefs were 
shattered by the evidence of microorganisms developing resistance against this treat-
ment. It is now accepted that infectious microorganisms cannot be indefinitely treated 
with antibiotics.1,2 For many medical procedures to remain viable treatments, novel 
therapeutic approaches to infections need developing in order to guarantee sufficient 
protection against pathogens. The use of metals, predominantly silver, in the form of 
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salts or nanoparticles is a well-established antimicrobial strat-
egy that found applications in creams,3 wound wrappings,4 
fabrics,5 and eluting surfaces.6–8 However, concerns regard-
ing the use of silver are growing, particularly its long-term 
safety linked to accumulation in the environment and the 
body,9,10 hence other antimicrobial agents are in urgent need. 
Chitosan,11 honey extracts,12 and phytochemicals13 are natural 
compounds that have shown promising results. Paraben is 
another class of nonantibiotic antimicrobial compounds; 
paraben is the common name of an ester of p-hydroxybenzoic 
acid (Figure S1). They are a class of compounds with anti-
bacterial and antifungal activity routinely used in cosmetics,14 
pharmaceutical products,15 food products,16 and catheter 
lock solutions.17 The mechanism of action of parabens is 
thought to be the inhibition of the synthesis DNA and RNA 
or ATPases and phosphotransferases, and more recently, the 
impact on the capacity of the bacteria to withstand osmotic 
imbalance.18
Orthopedic surgeries are procedures that generally require 
anti-infection therapy; despite the risk posed by antibiotic 
resistance, these compounds are still the normal approach. 
Antibiotics can be delivered either parenterally19,20 or through 
elution from bone cement,21–23 when the latter is used, it 
provides a quick and strong attachment between bone frac-
tures or bone and medical devices, like in the case of joint 
replacement procedures.24 Different types of bone cements 
are available and employed for different applications; for 
example, poly(methyl methacrylate) (PMMA) bone cement is 
used in joint replacements, providing high mechanical perfor-
mance and a quick setting time.24 Calcium phosphate cements 
(CPC), in spite of the excellent osteoconductive properties, 
are used in low load-bearing conditions such as bone defect 
treatments, because of their low mechanical strength and 
brittle behavior.24 Hydroxyapatite and brushite are some of the 
allotropic forms of calcium phosphate and the two CPC that 
are currently used.24 Both types of bone cement are applied 
as a paste; however, their hardening processes are different: 
in the case of PMMA, polymerization takes place, while dis-
solution and precipitation occur for the setting of CPC.
Notwithstanding the antibiotic cover provided pre- and 
postorthopedic procedures, the incidence of infections is still 
relatively high, in some cases up to 9%–10%.25,26 The onset of 
infections not only causes pain and discomfort, but sometimes 
can even be life-threatening to patients; moreover, infections can 
considerably increase the cost of treatment due to a greater num-
ber of medications and lengthened hospital stays required.
In this paper, organic nanoparticles containing propylpa-
raben were prepared through a recently described synthetic 
route, namely by solvent removal from a volatile oil-in-water 
microemulsion,27 and embedded in PMMA and calcium phos-
phate bone cement at different concentrations; their antimicro-
bial activity was determined against Staphylococcus spp. and 
Acinetobacter baumannii as model pathogens in postortho-
pedic infections. Once the effective concentration of these 
nanoparticles was determined, their effect on the mechanical 
and cytotoxic properties of bone cement was investigated.
Materials and methods
chemicals and nanoparticles preparation
Propylparaben was supplied by Sharon Laboratories 
(Ashdod, Israel), while all other chemicals were purchased 
from Sigma-Aldrich (Gillingham, UK and Rehovot, Israel), 
unless otherwise stated, and solutions were prepared accord-
ing to standard laboratory practice.
Organic nanoparticles were prepared according to the 
procedure developed by Margulis-Goshen et al.27 Briefly, a 
microemulsion composed of propylparaben 3% w/w, n-butyl 
acetate 3.5% w/w, iso-propyl alcohol 3.5% w/w, sodium 
dodecyl sulfate (SDS) 8% w/w, polyvinylpyrrolidone (PVP) 
40,000 7% w/w, and water 75% w/w was spontaneously 
formed upon mixing of all components at room temperature. 
Fast, simultaneous removal of the solvents and water from 
the microemulsion by spray drying led to the formation of a 
fine powder composed of propylparaben nanoparticles, SDS, 
and PVP. The composition of the resulting powder was pro-
pylparaben 16% w/w, SDS 45% w/w, and PVP 39% w/w.27 
The nanoparticles were readily dispersible in water, yielding 
a stable dispersion of particles with approximate diameter 
of 16 nm as indicated by small angle X-ray scattering, and 
had a zeta potential in NaCl 10 mmol of −46 mV.27 It was 
found that in this system, almost all propylparaben (about 
98% w/w) was present as nanosized particles.27
Bacteria
Gram-positive bacteria Staphylococcus aureus (NCIMB 
9518), methicillin-resistant S. aureus – MRSA (NCTC 12493), 
and Staphylococcus epidermidis (RP62a) along with Gram-
negative bacterium Acinetobacter baumannii (NCIMB 9214) 
were used. Bacteria frozen stokes were stored at −80°C; strains 
were streaked on BHI plates weekly (Oxoid Ltd, Basingstoke, 
UK) and incubated for 24 hours at 37°C, then stored at 4°C.
Bone cement preparation and 
characterization
PMMA-based bone cement was obtained by mixing PMMA 
(Lucite International, Darwen, UK) (4.1 g), barium sulfate 
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(0.46 g), benzoyl peroxide (0.1 g), methyl methacrylate 
(1.96 g), and N,N-dimethyl-p-toluidine (0.04 g).
Calcium phosphate-based bone cement was prepared 
according to the procedure described by Ewald et al.28 
Hydroxyapatite bone cement was obtained by mixing sin-
tered α-tricalcium phosphate (α-TCP) (Fluka, Gillingham, 
UK) (12 g) with Na
2
HPO
4
 2.5% w/v (4 mL), while brushite 
bone cement was prepared by mixing sintered β-tricalcium 
phosphate (β-TCP) (6.62 g) with Ca(H
2
PO
4
)
2
 (5.38 g) and 
citric acid 0.05 M (4 mL).
For each bone cement, the solid and liquid phases were 
mixed in a beaker and poured into a mold that allowed the 
preparation of cylindrical specimens (6 mm in diameter and 
12 mm in height), at an approximate setting time of 1 minute. 
The filled mold was pressed between two glass plates for 
24 hours, and the cement was allowed to harden before the 
samples were extracted. Bone cement samples were stored in 
dark, sterile conditions (for no more than 3 days) prior to use.
The organic nanoparticles were added to the solid phase 
prior to mixing with the liquid phase, these were added with 
specific quantities to achieve a final concentration of 0.1%, 
0.5%, 1%, 2%, 5%, and 7% w/w; bone cement of the appropri-
ate type (PMMA, hydroxyapatite, or brushite) not containing 
nanoparticles was used as a control sample (0% w/w).
antimicrobial activity of organic 
nanoparticles and the bone cements
Approximately 15 mL of fresh sterile BHI broth (Oxoid 
Ltd) was inoculated with cells and incubated statically for 
24 hours at 37°C.
The antimicrobial activity of the organic nanoparticles 
was compared with the activity of pure compounds (propyl-
paraben, SDS, PVP) and their mixture before nanoparticles 
synthesis, determined through standard minimal inhibitory 
concentration (MIC) protocol.
Bone cement samples (cylindrical, 12 mm long, with 
a diameter of 6 mm) were placed in a 24-well plate, with 
a covering of 2 mL of the bacterial suspension (described 
before). The 24-well plate was incubated for 1 hour at 
37°C statically, the bacterial suspension was removed 
and the samples were rinsed three times with fresh sterile 
phosphate buffer solution (PBS). Around 1 mL of a diluted 
solution of sterile BHI broth in PBS (1/10 BHI) was added 
to each sample, and the plate was incubated at 37°C. After 
24 hours, 50 μL from each well was transferred to a 100-well 
plate (Bioscreen C; Labsystems Diagnostics Oy, Helsinki, 
Finland) containing 100 μL of fresh sterile BHI broth. 
The bacterial growth curves at 37°C were recorded every 
15 minutes through optical density (OD) at 600 nm (OD
600
), 
using a plate reader (Bioscreen C analyzer; Labsystems 
Diagnostics Oy).
All tests were performed in triplicate and on three inde-
pendent cultures, resulting in nine growth curves for each 
bacterium on each bone cement sample. Each growth curve 
was fit using the Gompertz growth model to extract values 
of lag phase and growth rate. Results are presented as mean 
and standard deviation.
Water uptake
Bone cement samples containing paraben nanoparticles and 
controls were incubated in 5 mL PBS at 37°C for 3 months; 
for the first 2 weeks, the samples were weighed daily; after 
a fortnight the samples were weighed every 3 days.
compression testing of composite bone 
cements
Compression tests were performed according to BS ISO 
5833:2002 on the Zwick Roell ProLine table-top Z050/Z100 
materials testing machine (Zwick Roell, Ulm, Germany). 
Cylindrical samples 12 mm long with a diameter of 6 mm 
were employed. The compression tests were conducted 
at a constant crosshead speed of 20 mm/min to produce a 
curve of displacement against load. Tests were performed 
on bone cement samples with the following concentrations 
of organic nanoparticles (7% w/w for PMMA, 5% w/w for 
hydroxyapatite, and 1% w/w for brushite) freshly prepared 
and after 1 week immersion in PBS at 37°C. The compressive 
strength of the bone cement was determined by dividing the 
force applied to cause fracture by the original cross-sectional 
area of the cylinder. The average compressive strength of 
five specimens was calculated.
In vitro cytotoxicity studies on composite 
bone cements
Osteoblast cells (MC-3T3) were cultured in Dulbecco’s 
Modified Eagle’s Medium (DMEM) supplemented with 
fetal bovine serum (10% v/v), cells were incubated at 37°C 
in humidified atmosphere with 5% CO
2
. Cells were grown 
until a 70% confluency was achieved, washed twice with 
sterile PBS, and detached with trypsin; osteoblast cells were 
counted (using trypan blue to differentiate between viable and 
nonviable cells) and diluted to a concentration 105 cells/mL 
with fresh medium.
Prior to use, all bone cement samples (controls 
without nanoparticles and with organic nanoparticles 
7% w/w for PMMA, 5% w/w for hydroxyapatite, and 
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1% w/w for brushite) were sterilized using 70% alco-
hol and washed three times with sterile PBS. Samples 
were placed in 24-well plates containing 2 mL of 
osteoblast cell suspension (prepared as described 
before). Osteoblasts were cultured on the bone cement 
samples at 37°C in humidified atmosphere with 
5% CO
2
. The viability of osteoblast cells was assessed 
using the MTT enzyme assay protocol (Invitrogen, Pais-
ley, UK). The MTT solution was prepared according to 
the manufacturer guidelines and 10 μL was added to each 
well. After incubation for 2 hours at 37°C in humidified 
atmosphere with 5% CO
2
, the samples were transferred to 
a sterile 24-well plate and the MTT solubilization solution 
was added. When full dissolution of the crystals occurred, 
100 μL of liquid was transferred to a sterile 96-well plate, 
and the absorbance of each sample was read at 540 nm 
(OD
540
). Results are presented as the average and standard 
deviation of three independent bone cement samples.
Propylparaben release from bone cement
Bone cement samples containing paraben nanoparticles, pre-
pared as described in “Bone cement preparation and charac-
terization” (with organic nanoparticles 7% w/w for PMMA, 
5% w/w for hydroxyapatite, and 1% w/w for brushite), were 
incubated in 2 mL PBS at 37°C; the solution was replaced 
daily with fresh PBS and analyzed to quantify the amount 
of propylparaben released using reverse-phase HPLC. An 
Agilent series 1100 HPLC system was equipped with a 
Waters Spherisorb® (Sigma-Aldrich, St Louis, MO, USA) 
5 μm ODS2 (4.6×150 mm) analytical column thermostated 
at 25°C. The injection volume was 5 μL, the mobile phase 
was water:acetonitrile 50:50, with a flow rate of 1 mL/min, 
and the detector was a UV spectrophotometer at 254 nm. An 
example of a chromatogram for a 1 mg/mL solution of pro-
pylparaben in DMSO is shown in Figure S2; the calibration 
curve of the HPLC detection of propylparaben is presented 
in Figure S3.
Bone cement settling time
The influence of the paraben nanoparticles on the bone 
cement settling time was determined through rheologi-
cal tests using AR-G2 (TA Instruments, Hertfordshire, 
UK), using 40 mm Peltier plates. Dynamic oscillation 
tests were performed; in these measurements, a sinu-
soidal oscillation strain (σ) of small amplitude (σ
0
) and 
frequency (ω):
 σ σ ωt i t( ) = 0 exp( )  (1)
was applied to the sample. The resulting stress (ω) was com-
pared with the strain giving the complex modu lus G*.
 G
t
t
* = ( )( )
σ
γ
 (2)
Because the two sinusoidal waves will have a phase 
difference, δ, the storage (G′) and loss modulus (G″) can be 
defined as the component in phase and π/2 out of phase with 
the strain, respectively.
 G G iG* = ′ + ′′  (3)
and
 ′ =G G * cosδ  (4)
 ′′ =G G * senδ  (5)
Analysis was carried out using dynamic time sweep test 
that takes successive measurements at constant frequency 
and strain at selected intervals. The test was conducted at a 
strain of 0.1% and fixed frequency of 1 Hz.
All three types of bone cement containing 2% w/w of 
gentamicin were analyzed along with samples with paraben 
nanoparticles 7% w/w for PMMA, 5% w/w for hydroxyapatite, 
and 1% w/w for brushite. The two phases were mixed quickly 
with a spatula, the mixture was deposited onto the lower plate, 
and experiments started as fast as possible. To account for the 
time elapsed during mixing and pouring, the timer was started 
at the moment of mixing the liquid with powders.
Measurement of complex Young modulus and phase 
angle were taken every 6 seconds for up to 2,500 seconds. 
Each sweep experiment was carried out on three indepen-
dently prepared cement samples, and results are presented 
as mean and standard deviation.
statistical analysis
The influence of paraben nanoparticles on mechanical and 
cytotoxic properties of bone cement was tested through 
ANOVA using SPSS (12.0) (SPSS Inc., Chicago, IL, 
USA). For all analyses, P,0.05 was considered statistically 
significant.
Results
antimicrobial activity of bone cements 
containing nanoparticles
In general, it was found that the nanoparticles of propylpa-
raben exhibited a significantly greater antimicrobial activity 
toward all bacteria tested than the propylparaben as raw 
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material powder without conversion into nanoparticles. 
The nanoparticles were also found to be more potent than 
the physical mixture of all nanoparticle components, which 
has shown MICs about twice as high as the nanoparticles 
(Table 1). SDS and PVP alone did not exhibit antimicrobial 
activity at the concentrations corresponding to the quantities 
present at the MIC characteristic of the nanoparticles (data 
not shown).
Examples of growth curves for each of the bacteria tested 
on all bone cement samples are presented in Figures 1–4. 
In all cases, when no antimicrobial nanoparticles were 
present, the OD
600
 quickly started to increase (lag phase about 
1–2 hours), reaching the stationary phase after 4–6 hours 
depending on the bacterium. With increasing concentration 
of nanoparticles, the lag phase duration expanded, when 
1% w/w was added to brushite, no growth was detected for 
all bacteria but MRSA, hydroxyapatite containing 5% w/w 
achieved the same results, while 7% w/w of nanoparticles 
were required for PMMA bone cements.
Generally, 0.1% w/w of nanoparticles in brushite gave 
growth curves not dissimilar to control samples, apart from 
S. aureus; 0.5% w/w in hydroxyapatite and 1% w/w in 
Figure 1 examples of Staphylococcus aureus growth curves on (A) brushite, (B) hydroxyapatite, and (C) PMMa containing antimicrobial organic nanoparticles.
Notes:  0%,  0.1%,  0.5%,  1%,  2%,  5%,  7%.
Abbreviations: NP, nanoparticle; OD600, optical density at 600 nm; PMMa, poly(methyl methacrylate).
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Table 1 MIc (μg/ml) of pure propylparaben, organic nanoparticles, 
and hand mixture of nanoparticles components
Bacteria NP Mixture of NP  
components
Propylparaben
S. aureus 80 160 2,500
Mrsa 80 160 1,250
A. baumannii 160 160 1,250
S. epidermidis 160 300 2,500
Abbreviations: MIc, minimal inhibitory concentration; Mrsa, methicillin-resistant 
Staphylococcus aureus; NP, nanoparticles; S. aureus, Staphylococcus aureus; A. baumannii, 
Acinetobacter baumannii; S. epidermidis, Staphylococcus epidermidis.
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PMMA were ineffective. The bacteria tested exhibited dif-
ferent responses to the antimicrobial compounds depending 
on the type of bone cement. For example, A. baumannii 
was the most affected by paraben in hydroxyapatite bone 
cement as it was the only one not able to grow with 1% w/w 
of nanoparticles, but was capable of surviving 0.5% w/w 
of nanoparticles in brushite bone cement, while S. aureus 
and S. epidermidis were not. MRSA was generally the least 
sensitive among the bacteria studied.
A more in-depth analysis of the growth curve is pre-
sented for each type of bone cement in Tables 2–4, where 
all growth rates are presented alongside the lag phases. It 
is evident that bacteria exposed to bone cements contain-
ing increasing concentrations of antimicrobial compounds 
exhibited generally slower growth rates due to a lack of 
growth detected.
cytotoxicity and mechanical properties 
of bone cements containing nanoparticles
The analysis of the possible influence of the paraben nanopar-
ticles on the cytotoxic (Figure 5) and mechanical (Figure 6) 
properties of the bone cement revealed that concentrations 
capable of preventing infections (1% w/w for brushite, 
5% w/w for hydroxyapatite, and 7% w/w for PMMA) had 
no adverse effects (P.0.05).
When immersed in fluids (PBS), the bone cement sam-
ples increased in weight during the first 4–5 days because 
of water uptake, and after that, the amount of fluid in the 
samples remained stable (data not shown). No  difference 
was observed between the different concentrations of 
propylparaben nanoparticles encapsulated in bone cement 
(P.0.05). Furthermore, the water uptake results in a 
lower compression strength of all types of bone cement, 
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Figure 2 examples of Mrsa growth curves on (A) brushite, (B) hydroxyapatite, and (C) PMMa containing antimicrobial organic nanoparticles.
Notes:  0%,  0.1%,  0.5%,  1%,  2%,  5%,  7%.
Abbreviations: Mrsa, methicillin-resistant Staphylococcus aureus; NP, nanoparticle; OD600, optical density at 600 nm; PMMa, poly(methyl methacrylate).
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Figure 3 examples of Acinetobacter baumannii growth curves on (A) brushite, (B) hydroxyapatite, and (C) PMMa containing antimicrobial organic nanoparticles.
Notes:  0%,  0.1%,  0.5%,  1%,  2%,  5%,  7%.
Abbreviations: NP, nanoparticle; OD600, optical density at 600 nm; PMMa, poly(methyl methacrylate).
regardless of the presence of propylparaben nanoparticles 
(Figure 6).
Propylparaben release from bone 
cements
The release of propylparaben (Figure 7) from the samples 
containing the same amount of nanoparticles also indicated 
that the totality of the paraben is released from the calcium 
phosphate bone cement, but only about 5% of the initial 
amount of propylparaben is released from PMMA. Further-
more, the samples were releasing propylparaben continuously 
for the first 3–4 days. The amount of propylparaben released 
from hydroxyapatite and brushite was almost an order of mag-
nitude higher than PMMA despite the initial concentrations 
in all three cases being very similar, and so was chosen as the 
minimum effective against the bacteria tested. Additionally, 
the concentration of propylparaben in the release medium for 
PMMA bone cement after 24 hours of elution, was closer to 
the MIC of the bacteria used in this study than the calcium 
phosphate bone cement that exhibited significantly higher 
concentrations of propylparaben than MIC.
settling times of bone cements containing 
nanoparticles
The possible influence of the organic nanoparticles on the 
kinetics of bone cement settling was investigated through 
the evolution of the rheological properties of bone cement 
dough after mixing (Figure 8). In all cases, the storage 
modulus (G′) was greater than the loss modulus (G″); the 
pattern followed a monotonic increase at an initial fast rate 
that slowed down reaching a plateau. For each type of bone 
cement, the presence of paraben nanoparticles required a 
slightly longer settling time (defined as the time needed 
for the dough to reach constant rheological properties). It 
was also evident that PMMA is the quickest type of bone 
cement to set (about 150 and 300 seconds for gentamicin 
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Figure 4 examples of Staphylococcus epidermidis growth curves on (A) brushite, (B) hydroxyapatite, and (C) PMMa containing antimicrobial organic nanoparticles.
Notes:  0%,  0.1%,  0.5%,  1%,  2%,  5%,  7%.
Abbreviations: NP, nanoparticle; OD600, optical density at 600 nm; PMMa, poly(methyl methacrylate).
and paraben containing bone cements, respectively), while 
hydroxyapatite required the longest (about 1,000 and 
2,000 seconds for gentamicin and paraben containing bone 
cements, respectively).
Discussion
Parabens uses and safety
Propylparaben exhibits hydrophobic properties, therefore 
its use is limited to nonwatery systems; we have shown that 
the encapsulation of this drug in nanoparticles increases 
the hydrophilicity, resulting in stable dispersions and 
employability in aqueous environments thus expanding its 
possible applications. Despite the widespread applications 
of parabens, some concerns were raised regarding their 
potential safety as concentrations in environmental samples, 
human blood, breast milk, and tissues of these compounds 
had been steadily growing.29 Possible estrogenic effects 
have been suggested,30 and as they have been also found in 
breast cancer tissues, this led to the suggestion that parabens 
can adversely influence breast cancer formation.31,32 How-
ever, evidence of in vivo paraben-induced developmental 
and reproductive toxicity lacks consistency and physi-
ological coherence as stated by Witorsch and Thomas.33 
After many reviews and research, their use was found to 
be safe.34,35
Infections and antimicrobial bone 
cements
The possibility of a microorganism to induce infection in a 
particular site of the body depends on its ability to survive 
and colonize that particular area; this is dictated by the envi-
ronmental conditions of that location. The most common 
sources of postorthopedic infections are S. aureus, MRSA, 
and S. epidermidis;36,37 more recently, A. baumannii has given 
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Table 2 lag phase and growth rate of the growth curves of survi-
val on brushite bone cement containing organic nanoparticles
Concentration of  
nanoparticles (% w/w)
λ (hour) Growth rate 
(hour−1)
S. aureus
0 1.18±0.12 0.25±0.07
0.1 6.61±1.06 0.35±0.14
0.5 .24 No growth
1 .24 No growth
5 .24 No growth
Mrsa
0 0.91±0.28 0.27±0.06
0.1 1.32±0.17 0.28±0.03
0.5 2.27±0.35 0.31±0.04
1 10.00±1.11 0.09±0.01
5 .24 No growth
A. baumannii
0 1.67±0.19 0.30±0.02
0.1 1.43±0.08 0.41±0.06
0.5 3.49±0.63 0.15±0.07
1 .24 No growth
5 .24 No growth
S. epidermidis
0 3.29±0.71 0.18±0.03
0.1 4.13±0.31 0.19±0.03
0.5 .24 No growth
1 .24 No growth
5 .24 No growth
Note: Mean ± standard deviation.
Abbreviations: S. aureus, Staphylococcus  aureus; A. baumannii, Acinetobacter baumannii; 
S. epidermidis, Staphylococcus epidermidis; Mrsa, methicillin-resistant Staphylococcus 
aureus.
Table 3 lag phase and growth rate of the growth curves of survival 
on hydroxyapatite bone cement containing organic nanoparticles
Concentration of  
nanoparticles (% w/w)
λ (hour) Growth rate 
(hour−1)
S. aureus
0 0.11±0.02 0.15±0.02
0.1 0.13±0.02 0.16±0.03
0.5 2.11±0.08 0.12±0.03
1 3.81±0.36 0.06±0.02
5 .24 No growth
Mrsa
0 1.25±0.22 0.27±0.03
0.1 1.44±0.26 0.31±0.05
0.5 2.25±0.35 0.31±0.04
1 10.02±0.73 0.26±0.07
5 .24 No growth
A. baumannii
0 2.29±0.36 0.22±0.01
0.1 2.34±0.43 0.18±0.02
0.5 1.78±0.13 0.20±0.02
1 .24 No growth
5 .24 No growth
S. epidermidis
0 1.60±1.24 0.17±0.00
0.1 1.23±0.55 0.14±0.01
0.5 2.12±0.25 0.14±0.02
1 8.45±1.27 2.42±5.22
5 .24 No growth
Note: Mean ± standard deviation.
Abbreviations: Mrsa, methicillin-resistant Staphylococcus aureus; S. aureus, 
Staphylococcus  aureus; A. baumannii, Acinetobacter baumannii; S. epidermidis, Staphylococcus 
epidermidis.
rise to concerns.38 The choice of bacteria tested in this work 
was based on such notions.
The antimicrobial protocols employed here are based 
on the assumption that bacteria attach to the bone cement 
sample during the initial contact with the suspension; cells 
capable of surviving the antimicrobial compound detach and 
are able to grow in the diluted broth.7,8,39 The growth curve 
using this suspension was recorded; the antimicrobial activity 
of the nanoparticles embedded in bone cement is positively 
linked to the length of the lag phase of the growth curves 
(Figures 1–4). Variations between samples are determined by 
the initial bacterial concentration in the broth containing the 
bone cement sample after 24 hours incubation post bacterial 
exposure. This is in virtue of the fact that cell concentrations 
below a certain threshold are not detectable through OD 
measurements, hence, the lower the initial cell concentration, 
the longer the time required to reach such cell numbers.40 
Additionally, the decreasing growth rates of the surviving 
bacteria exposed to increasing concentrations of nanoparticles 
(Tables 2–4) demonstrated that the antimicrobial effect is not 
only limited to a reduction of the viable microbial population, 
but is also an indication that the viable cells did not exhibit 
the same phenotype of the cells in contact with the paraben 
nanoparticles. This slower growth rate could be attributed to 
irreversible cell damage or to the release of sublethal amounts 
of antimicrobial agents from the bone cement samples.
The efficacy of the paraben nanoparticles embedded in 
bone cement appeared to follow the pattern indicated below: 
brushite . hydroxyapatite . PMMA (Tables 2–4). This 
could be attributed to the different settling temperatures of 
the materials as this is one of the most significant differences 
between the two bone cement types. For CPC, this is gener-
ally the body temperature, while for PMMA the temperature 
can reach up to 70°C−80°C during settling. Polymerization 
is an exothermic reaction and is the leading cause for bone 
damage at the interface between bone cement and bone.41 
Parabens are thermally stable42 and, therefore, temperature 
alone cannot be responsible for such decreased activity; 
however, radicals can interact with the paraben molecules and 
cause these molecules degradation, thus the active quantity 
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Gentamicin and tobramycin are the most common 
antibiotics used in PMMA bone cement43 in virtue of their 
thermal stability and broad spectrum; they are effective 
against β-lactam resistant strains such as MRSA. How-
ever, S. epidermidis strains such as RP62a and various 
Table 4 lag phase and growth rate of the growth curves of 
survival on PMMa bone cement containing organic nanoparticles
Concentration of  
nanoparticles (% w/w)
λ (hour) Growth rate 
(hour−1)
S. aureus
0 0.76±0.03 0.33±0.09
1 0.82±0.04 0.35±0.10
2 1.04±0.07 0.11±0.04
5 11.07±1.04 0.01±0.01
7 .24 No growth
Mrsa
0 0.82±0.16 0.18±0.01
1 1.23±0.11 0.27±0.06
2 1.19±0.13 0.24±0.04
5 9.39±0.67 0.28±0.07
7 .24 No growth
A. baumannii
0 1.91±0.02 0.20±0.01
1 1.96±0.28 0.28±0.04
2 2.64±0.50 0.13±0.02
5 10.82±1.16 0.08±0.01
7 .24 No growth
S. epidermidis
0 1.32±0.08 0.15±0.03
1 1.39±0.04 0.16±0.03
2 2.03±0.24 0.08±0.04
5 9.24±0.42 0.04±0.02
7 .24 No growth
Note: Mean ± standard deviation.
Abbreviations: Mrsa, methicillin-resistant Staphylococcus aureus; PMMa, 
poly(methyl methacrylate); S. aureus, Staphylococcus  aureus; A. baumannii, Acinetobacter 
baumannii; S. epidermidis, Staphylococcus epidermidis.
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Abbreviation: PMMa, poly(methyl methacrylate).
remaining after bone cement settling is lower than the initial 
amount, requiring a greater quantity in PMMA bone cement 
to achieve the same results as in CPC. Furthermore, the dif-
ferent porosity of the bone cements can be a cause of the 
different antimicrobial agent release.
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A. baumannii, both tested in this work, are resistant to these 
drugs,44,45 rendering the use of these two antibiotics ineffec-
tive when such strains are involved. We tested the three types 
of bone cements supplemented with gentamicin 2% w/w (the 
commercial formulation of this antibiotic in bone cement) 
against the four pathogens, and the growth of S. epidermidis 
was not prevented (Figure S4). Our results demonstrated that 
organic nanoparticles made of propylparaben are effective 
against a wide range of bacteria, including antibiotic-resistant 
strains (Figures 3 and 4) found in orthopedic infections; 
hence, the use of these organic nanoparticles could offer not 
only a possible alternative to antibiotics, but also solve some 
of the problems already associated with antibiotic resistance. 
Moreover, the amount of paraben nanoparticles required 
to provide effective antimicrobial activity is similar to the 
amount of gentamicin and tobramycin used (2%–4% w/w) 
and is significantly lower than other antimicrobial agents, 
such as chitosan11 and quaternized chitosan derivative,44 that 
require about 20%–30% w/w.
Despite providing antimicrobial activity, in order to be 
a viable option, the organic nanoparticles must not induce 
negative effects on the other bone cement properties. For 
this reason, the cytotoxicity and compression strength of 
bone cements containing the amount of nanoparticles suf-
ficient to exhibit antimicrobial capacity (7% w/w for PMMA, 
5% w/w for hydroxyapatite, and 1% w/w for brushite) were 
determined. The results demonstrated that the nanoparticles 
did not have a detrimental effect on these two essential 
characteristics (Figures 5 and 6).
The release of propylparaben from the bone cement 
samples demonstrated a typical elution profile (Figure 7). 
However, the antimicrobial activity of the samples did not 
appear to be exclusively dependent on the amount of paraben 
released. For example, PMMA containing 7% w/w nanopar-
ticles was as effective as 1% w/w in brushite, but returned 
a lower concentration in the medium. As the protocol to 
assess the antimicrobial activity employed in this work is 
based on the survival of the cells attached to the surface of 
$ %
&







      7LPHVHFRQGV







     7LPHVHFRQGV
*′*
″ 3
D
*′*
″3
D







      7LPHVHFRQGV
*′*
″3
D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Note: Full symbols (G′) and empty symbols (G″).
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the sample,6–8,39 then for a material to exhibit antimicrobial 
activity, it is not required for the drug in question to elute. The 
hydrophobicity of propylparaben is likely to be the reason 
for its low concentration in the medium when partitioning 
between PMMA and water. Additionally, no propylparaben 
remained embedded in the samples as the cumulative release 
reached 100% of the initial amount; however, this was not 
the case for PMMA where only about 5% was released. The 
entrapment of other antimicrobial compounds (such as antibi-
otics) in PMMA bone cement is a well-known phenomenon, 
and in our particular case, it could be a consequence of the 
hydrophobicity of propylparaben or of its inactivation during 
the polymerization.
Material properties of bone cements
The time needed for the bone cement to develop the final 
mechanical properties (settling time) is a critical parameter 
that dictates operating procedures, both during application 
and after during patient recovery. Therefore, the introduction 
of the paraben nanoparticles into the bone cement formula-
tion must not result in settling time greatly dissimilar from 
bone cement containing the commonly used gentamicin 
(2% w/w). We have proved (Figure 8) that the settling time 
of all three types of bone cements was slightly longer when 
paraben nanoparticles are present compared to gentamicin 
using rheological testing that is a standard procedure to 
investigate bone cement formulations. It appears that the 
use of the novel antimicrobial agents would not alter the 
already established procedures for the application of bone 
cement that are being employed. The profiles we detected 
are also comparable to those presented by others,46 par-
ticularly the similar values of G′ and G″ for PMMA bone 
cement.47
Conclusion
Parabens are nonantibiotic antimicrobial compounds widely 
used in consumer products and considered safe as no satisfac-
tory evidence has been found indicating any possible links 
to adverse effects.
We have demonstrated in this work that nanoparticles 
made from parabens can be used in bone cement to prevent 
the onset of infections. The efficacy depends on the type of 
bone cement, for example, calcium phosphate bone cements 
require a lower amount of parabens than the acrylic type 
(PMMA) in virtue of the lower settling temperature of the 
former. Our results prove that parabens could be employed 
in bone cement as alternatives to antibiotics, whose activ-
ity is gradually decreasing as a consequence of the rise in 
antibiotic-resistant microorganisms. Furthermore, the para-
ben nanoparticles are effective also against bacterial strains 
already resistant to some of the common antibiotics used in 
bone cements. No detrimental effect was detected on either 
compression strength or cytotoxicity of the bone cement 
when the paraben nanoparticles were added.
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